MorphoSys AG
XETRA:MOR

Watchlist Manager
MorphoSys AG Logo
MorphoSys AG
XETRA:MOR
Watchlist
Price: 67.25 EUR 0.37% Market Closed
Market Cap: €2.5B

Operating Margin

-216.4%
Current
Declining
by 111.8%
vs 3-y average of -104.6%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-216.4%
=
Operating Income
€-440.4m
/
Revenue
€203.5m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-216.4%
=
Operating Income
€-440.4m
/
Revenue
€203.5m

Peer Comparison

Country Company Market Cap Operating
Margin
DE
MorphoSys AG
XETRA:MOR
2.5B EUR
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
387B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
174.7B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.5B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
44B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Lower than 95% of companies in Germany
Percentile
5th
Based on 3 747 companies
5th percentile
-216.4%
Low
-61 459.6% — 0.7%
Typical Range
0.7% — 9.8%
High
9.8% — 94 540%
Distribution Statistics
Germany
Min -61 459.6%
30th Percentile 0.7%
Median 4.5%
70th Percentile 9.8%
Max 94 540%

MorphoSys AG
Glance View

Market Cap
2.5B EUR
Industry
Biotechnology

MorphoSys AG emerged from the vibrant biotechnology landscape of Munich, Germany, in 1992. It was founded on the innovative idea of harnessing antibodies as a means to combat diseases. With a precision-driven approach to drug development, MorphoSys primarily concentrates on creating and bringing to market therapeutic agents for cancer and inflammatory disorders. Taking center stage is their proprietary technology platform that enables the discovery of monoclonal antibodies, pivotal in the fight against these daunting ailments. This platform not only serves their internal pipeline but also provides a significant source of revenue through collaborations and licensing agreements with major pharmaceutical giants, enabling MorphoSys to strike timely alliances that bolster both innovation and profitability. Central to MorphoSys's business model is its dual focus: advancing its own pipeline of antibody-based therapeutics while simultaneously offering its technological platforms to partners. This symbiosis allows the company to generate revenue through milestone payments and royalties as partnered drugs advance through clinical trials and into the market. A key asset in its lineup is Monjuvi, a groundbreaking treatment for lymphoma, which underscores the firm's capability to evolve from tech-driven operations to delivering market-ready solutions. As markets grow increasingly competitive, MorphoSys's strategic prowess lies in balancing its R&D investments with collaborative ventures, ensuring a steady revenue stream and a robust presence in the biopharmaceutical realm.

MOR Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-216.4%
=
Operating Income
€-440.4m
/
Revenue
€203.5m
What is MorphoSys AG's current Operating Margin?

The current Operating Margin for MorphoSys AG is -216.4%, which is below its 3-year median of -104.6%.

How has Operating Margin changed over time?

Over the last 3 years, MorphoSys AG’s Operating Margin has decreased from -162.3% to -216.4%. During this period, it reached a low of -216.4% on Apr 2, 2024 and a high of -73.3% on Jun 30, 2023.

Back to Top